Sarepta announces EU regulators temporarily halted dosing of ELEVIDYS
Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular ...
Sarepta halts three studies testing gene therapy for muscle disorder
Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.
Sarepta sinks 9% after Elevidys studies placed on hold in Europe
The shares are down 9%, or $5.53, to $56.94 in premarket trading. Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended ...